pharmacogenomics

January 10, 2023

Anti-nausea drug response in children

Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.

September 2, 2021

Study shows gene-drug interactions are common

When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing.

Medical laboratory scientist Gladys Garrison, MT, MS, loads reagents to prepare DNA samples for analysis in the VUMC Molecular Diagnostics Lab.
April 30, 2020

PREDICT program expands, opens new Genomics Clinic

A new clinic opening at Vanderbilt University Medical Center will help doctors and patients choose the best drugs for their medical conditions based on the patients’ unique genetic makeup.

September 23, 2019

Tailoring treatment for heart defect

By defining the clinical and genetic factors that predict treatment response, Vanderbilt investigators aim to personalize therapy for a common heart complication in preterm infants.

October 1, 2015

Collaboration seeks to develop new therapies for bone, other diseases

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

July 9, 2015

VUMC lands major pharmacogenomics grant

Vanderbilt University Medical Center has received a five-year, $12.8 million grant from the federal government to develop better ways to predict how patients will respond to the drugs they’re given.